Webinar PresentationDate: June 11th, 2013Novartis Thalassemia App Challenge
On today’s call:JL NeptuneSenior Vice PresidentHealth 2.0Aya Yamaura-TimmsProduct Director,EXJADE Global Brand TeamNovartis OncologyGraeme OsseyChallenge ManagerHealth 2.0Laszlo DankoSenior DirectorEXJADE Global Brand TeamNovartis Oncology
Agenda for Today’s Meeting Novartis Oncology Overview Thalassemia Background Challenge & Goals About the Phases Evaluation Criteria Timeline Q & A
Novartis Oncology Overview Novartis Oncology has become a global leader in oncology and hematologythrough targeted research and open partnership in the pursuit of newtherapies capable of transforming outcomes for people with cancer and otherhematological diseases. We offer a wide range of innovative therapies to help physicians meet patientneeds, with one of the broadest and most comprehensive oncology pipelinesin the industry. Our research is driven by a distinctive scientific and clinicalstrategy, focusing on unmet medical needs and disease pathways. For more information about how we are transforming the treatment of cancerand other diseases, visit www.novartisoncology.com.
Thalassemia Background Diverse family of genetic disorders affecting red blood cell production, causinganemia and significant complications.1 Thalassemia can range from milder types to severe cases starting in infancyand require regular blood transfusions for patient survival.2 Clinical complications can vary by type, and patients suffer from iron overloadin their bodies as a consequence of the disease or because of extra ironabsorbed from transfusions.3 Most patients with thalassemia are of South and Southeast Asian,Mediterranean or Middle East origin, with immigration broadening the globalprevelance.41. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews. 2012:26S:S3-S62. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication ratesacross a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115:1886-1892.3. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Reviews. 2012;26S:S16-19.4. Thalassaemia International Federation. The Thalassaemia International Federation’s (TIF) New Focus: Addressing the Management of Non-Transfusion-DependentThalassaemias (NTDT). Position Paper 5.2. March 20, 2012. Accessed at: http://www.thalassaemia.org.cy/pdf/NTDT_Position_Paper_Final.pdf.
The ChallengeNovartis challenges the teams to develop an innovativesmartphone/iPad application that increases Thalassemia patients’ (aswell as the caretakers’) ability to manage the disease effectively andhelp patients live active lives despite their condition, in ways including: Monitoring/tracking of key parameters Treatment/medication adherence Recording of daily personal facts
Thalassemia Disease Management App7Patient(THAL App is on smartphone )HCPPatient(THAL App is on smartphone ) Key metrics Motivational factors Gamification/Edutainment Geo-targeting•Help Thalassemia patients communicatebetter with their doctors and manage thedisease better•Improved monitoring and complianceleading to better outcome
App Challenge Goals Teams should be BOLD and INNOVATIVE in developing solutions that:• Motivate, inspire and reinforce positive behaviors related to adherence• Enable patients to set and track goals, motivated by gaming features,“awards”/incentives, daily inspiration, etc.• Provide users ability to share information and collaborate with others(most importantly with their doctors)• Educate, entertain and keep patient up-to-date on disease and lifestyle topics
The Challenge Phase I – Ideation• Submission requirements: concept mock-up and documentation• Awards: 5 finalists awarded $5,000 each and continue to Phase II Phase II – Development• Eligibility: Phase I finalist• Submission requirements: demo video, slide deck, and live demoplus submission of app for testing• Awards: First Place $100,000Second Place $20,000Third Place $5,000
Evaluation Criteria Phase I• Creativity, innovation and unique qualities of application- (i.e. Game and/or gamification design characteristics that clearly driveengagement and experience)• Design, usability and intuitiveness of application• User appeal (simple and attractive interface) and potential forwidespread adoption (global audience)• Capability for the app to be connected (via opt-in-feature) to the tools(smartphones, tablets, PCs) used by HCPs for sharing of data• Potential of partnership and future work with Novartis
Evaluation Criteria Phase II• All phase I criteria• Degree of development of application- (prototype vs. polished product)
Timeline Phase I submission deadline: June 30, 2013• Evaluation Period: July 1 – 12, 2013• Notification to Finalists: Week of July 15, 2013 Phase II submission deadline: Sept. 8, 2013• Live, Virtual Judging: Sept. 10, 2013 Winner announced:October 1, 2013Health 2.0 Fall 2013 ConferenceSanta Clara, CA
Resources Thalassemia International Federation - http://www.thalassaemia.org.cy/ Cooley’s Anemia Foundation - http://www.thalassemia.org/ Novartis Iron Health Alliance - http://www.ironhealthalliance.com/index.jsp United Kingdom Thalassaemia Society, or UKTS - http://www.ukts.org/ Thalassemia Foundation of Thailand - http://www.thalassemia.or.th/index.html Thalassemia Patients and Friends (ThalPal - USA) -http://www.thalassemiapatientsandfriends.com/ Thalassemics India - http://www.thalassemicsindia.org/ National Thalassemia Welfare Society (India) -http://thalassemiaindia.org/index.php